Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ocular Manifestations in Rheumatic Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03753893
Recruitment Status : Active, not recruiting
First Posted : November 27, 2018
Last Update Posted : November 27, 2018
Sponsor:
Information provided by (Responsible Party):
Janet Pope, Lawson Health Research Institute

Brief Summary:
This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

Condition or disease Intervention/treatment
Uveitis Conjunctivitis Keratoconjunctivitis Sicca Xerophthalmia Eye Hemorrhage Optic Neuritis Papilledema Orbital Diseases Retinal Vein Occlusion Retinal Artery Occlusion Macular Edema Retinitis Chorioretinitis Iridocyclitis Scleritis Choroid Hemorrhage Blindness Amaurosis Fugax Other: No intervention used

Detailed Description:

For the purposes of determining the prevalence of ocular complications in inflammatory rheumatic diseases, the following search terms were used: conjunctivitis, keratoconjunctivitis sicca, xerophthalmia, uveitis, eye hemorrhage, optic neuritis, papilledema, orbital disease, retinal artery/vein occlusion, macular edema, retinitis, chorioretinitis, scleritis, iridocyclitis, choroid hemorrhage, blindness and amaurosis fugax.

These terms were searched in the context of a corresponding inflammatory disease on Medline, Cochrane and Web of Science from their inception (1966, 1991 and 1990 respectively) until the point of study completion.

Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in an inflammatory rheumatic disease. Studies were excluded if they were review articles, case reports where all patients experienced the same ocular comorbidity, if different comorbidities were not grouped independently, and if the study reported on fewer than 20 patients. When the same study cohort was used in more than one analysis, the most recent or largest sample-size study was included. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to assess the quality of cohort, case-control, and cross-sectional studies.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 1 participants
Observational Model: Ecologic or Community
Time Perspective: Retrospective
Official Title: Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases
Actual Study Start Date : May 1, 2013
Estimated Primary Completion Date : October 1, 2019
Estimated Study Completion Date : October 1, 2019



Intervention Details:
  • Other: No intervention used
    no intervention used


Primary Outcome Measures :
  1. Prevalence of ocular manifestations of inflammatory rheumatic diseases [ Time Frame: data is collected once per year up to 2020 ]
    Prevalence of ocular manifestations of inflammatory rheumatic diseases



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with ocular involvement in inflammatory rheumatic disease
Criteria

Inclusion Criteria:

  • Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in inflammatory rheumatic disease

Exclusion Criteria:

  • review articles,
  • case reports where all patients experienced the same ocular comorbidity
  • if different comorbidities were not grouped independently
  • if the study reported on fewer than 20 patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03753893


Sponsors and Collaborators
Lawson Health Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Janet Pope, MD Lawson Health Research Institute

Layout table for additonal information
Responsible Party: Janet Pope, Professor of Medicine, Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT03753893     History of Changes
Other Study ID Numbers: MTJP001
First Posted: November 27, 2018    Key Record Dates
Last Update Posted: November 27, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhage
Macular Edema
Uveitis
Conjunctivitis
Retinal Vein Occlusion
Retinitis
Rheumatic Diseases
Collagen Diseases
Neuritis
Keratoconjunctivitis
Optic Neuritis
Blindness
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Scleritis
Retinal Artery Occlusion
Papilledema
Chorioretinitis
Xerophthalmia
Iridocyclitis
Orbital Diseases
Amaurosis Fugax
Eye Hemorrhage
Choroid Hemorrhage
Pathologic Processes
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Uveal Diseases